{"id":3037,"date":"2026-09-10T08:20:00","date_gmt":"2026-09-10T12:20:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3037"},"modified":"2026-09-10T19:57:34","modified_gmt":"2026-09-10T23:57:34","slug":"lantern-phase-iii-supports-nasal-photodisinfection-before-surgery","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3037","title":{"rendered":"LANTERN Phase III Supports Nasal Photodisinfection Before Surgery"},"content":{"rendered":"

Evidence<\/strong> Regulatory disclosure · Discovery<\/strong> September 10, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Positive<\/p>\n

\"LANTERN<\/p>\n

Summary<\/h4>\n

Ondine Biomedical reported that the 5,188-patient Phase III LANTERN trial met its prespecified primary endpoint: adding a single preoperative nasal photodisinfection procedure to standard care produced an estimated 40.5% reduction in 30-day surgical-site-infection risk. The primary Bayesian analysis yielded a 98.2% posterior probability of benefit and a risk ratio of 0.60 with a 95% credible interval of 0.33 to 0.97. Three exploratory frequentist models were directionally consistent and statistically significant. No treatment-related significant adverse events were reported, and the product is not yet FDA approved.<\/p>\n

What Happened<\/h4>\n

LANTERN was a cluster-randomized, crossover, standard-of-care-controlled superiority study conducted at 18 hospitals in the United States and Canada. It enrolled patients undergoing cardiac, orthopedic, vascular, neurosurgical, radical-mastectomy and other major procedures. Standard care could include a mupirocin regimen, making the result relevant to an active decolonization workflow rather than an untreated comparator. Three exploratory frequentist analyses reported odds ratios of 0.47 to 0.48, p values of 0.016 to 0.022 and 95% confidence intervals extending from approximately 0.25 to 0.88. The company plans a pre-NDA meeting with FDA; detailed analyses, scientific presentation and peer-reviewed publication are pending.<\/p>\n

Deep Analysis<\/h4>\n

A clinically useful point-of-care decolonization tool:<\/strong> A five-minute, healthcare-administered, non-antibiotic procedure could avoid the adherence burden and resistance pressure of multiday topical antibiotics. Large enrollment, multicenter conduct and consistent alternative models support a real preventive effect. The missing absolute event rate is crucial: a substantial relative reduction can still yield a modest number needed to treat when baseline infection incidence is low.<\/p>\n

Model and cluster effects may overstate portability:<\/strong> Cluster randomization and crossover fit hospital workflow but increase sensitivity to site, period, procedure-mix and infection-surveillance effects. Agreement across exploratory models is reassuring, but a complete prespecified analysis, intracluster assumptions and site-level robustness are needed before the effect size can be treated as portable.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: 5,188 participants; 18 hospitals; prespecified Bayesian primary endpoint met; risk ratio 0.60; 98.2% posterior probability of benefit; three supportive frequentist models; no reported treatment-related significant adverse events. Missing facts: absolute infections, pathogen breakdown, procedure subgroups, secondary endpoints and FDA feedback. Upgrade evidence would be peer-reviewed concordant results, favorable absolute risk reduction and regulator agreement on an NDA path.<\/p>\n

Company and Product Background<\/h4>\n

Ondine Biomedical is a Canadian life-sciences company developing light-activated antimicrobial therapies. Its lead nasal photodisinfection product is branded Steriwave outside the United States and is authorized for nasal decolonization in Canada, the United Kingdom and certain other markets. In the United States it remains investigational.<\/p>\n

The procedure applies a proprietary photosensitizing agent inside the nose and activates it with red light, generating oxidative antimicrobial effects against bacteria, viruses and fungi. The nose is a reservoir for pathogens that can seed surgical sites; the platform is intended to reduce microbial burden immediately before surgery without relying on organism-specific binding or antibiotic susceptibility.<\/p>\n

InSilens Take<\/h4>\n

LANTERN is a material late-stage result because it tests an antimicrobial platform in a large, pragmatic hospital setting and reports both a prespecified Bayesian success and consistent frequentist sensitivity analyses. The current signal is positive, but the headline relative reduction is not enough to define clinical value or regulatory probability. Absolute infection counts, cluster diagnostics, subgroup consistency and a clear FDA submission pathway are the next decision-grade evidence.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — a large Phase III trial met its primary infection-prevention endpoint for a non-antibiotic platform with broad hospital relevance<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — the prespecified analysis favored treatment, while complete data and regulatory alignment remain pending<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — trial design and topline statistics disclosed through a dated regulated announcement<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — clinical magnitude, robustness across clusters and procedures, and FDA requirements are not yet established<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Ondine Biomedical reported that the 5,188-patient Phase III LANTERN trial met its prespecified primary endpoint: adding a single preoperative nasal photodisinfection procedure to standard care produced an estimated 40.5% reduction in 30-day surgical-site-infection risk….<\/p>\n","protected":false},"author":1,"featured_media":3047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[684,687,685,686],"class_list":["post-3037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-ondine-biomedical","tag-photodisinfection","tag-steriwave","tag-surgical-site-infection"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3037"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3037\/revisions"}],"predecessor-version":[{"id":3057,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3037\/revisions\/3057"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3047"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}